Table 1.
Patients’ mutations, clinical characteristics and immunological profile.
Patient | Age (years) | Sex | Genetic defect | Mutation | CD3+ cells/μl (nv) (34) | CD3+CD4+ cells/μl (nv) (34) | CD3+CD8+ cells/μl (nv) (34) | CD19+ cells/μl (nv) (34) | CD16+CD56+ cells/μl (nv) (34) | IgG g/l (nv) (35) | IgA g/l (nv) (35) | IgM g/l (nv) (35) | Clinical manifestations | Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pt. 1 | 15 | F | CD40 | c. 408A>T EX5 skipb | 2,000 (1,000–2,000) | 1,507 (400–2,000) | 356 (200–800) | 438 (200–600) | 302 (100–700) | 1.80 (6.4–19) | <0.06 (0.6–3) | 0.80 (0.6–3) |
|
IVIG, TMP–SMZ |
Pt. 2 | 31 | M | AICDA | c.441C>Ab; p.C147X; | 6,267 (600–2,000) | 908 (400–1,200) | 4,092 (200–800) | 136 (100–500) | 348 (100–500) | <0.35 (6.4–19) | <0.06 (0.6–3) | 43.90 (0.6–3) |
|
SCIG |
Pt. 3 | 3 | F | AICDA | c.389A>Cb; p.H130P; | 2,735 (1,200–4,000) | 1,006 (600–2,200) | 1,172 (400–1,400) | 480 (300–1,500) | 914 (100–800) | <0.6 (4.6–17) | <0.02 (0.3–1.7) | 6.80 (0.6–2.6) | Recurrent respiratory infections | IVIG |
Pt. 4 | 14 | F | AICDA | c.70C>Tb p.R24W | na | na | na | na | na | na | na | na | Recurrent respiratory infections | na |
Pt. 5 | 14/19a | M | CD40LG | c.346+4G>C | 2,264 (800–1,800) | 1,485 (400–1,200) | 636 (200–800) | 813 (100–500) | 177 (100–700) | 0.18 (6.4–19) | 0.02 (0.6–3) | 1.56 (0.6–3) | na | na |
Pt. 6 | 4 | M | CD40LG | c.487G>T; p.V163F | 3,490 (1,200–4,000) | 2,825 (600–2,200) | 537 (400–1,400) | 1,056 (300–1,500) | 251 (100–800) | <0.6 (5.3–19.6) | <0.02 (0.4–2.6) | 2.60 (0.5–3) | Recurrent respiratory infections | IVIG, AZM |
Pt. 7 | 3 | M | CD40LG | p.T254P | na | na | na | na | na | na | na | na |
|
na |
Pt. 8 | 7 | M | CD40LG | c.761C>T; p.T254M | 4,275 (800–3,200) | 3,198 (400–2,000) | 844 (400–1,400) | 791 (200–1,000) | 192 (100–700) | <0.45 (6.3–10) | <0.04 (0.4–3) | 3.75 (0.6–2.6) |
|
IVIG, TMP–SMZ |
Pt. 9 | 30 | M | CD40LG | p.C682T | na | Na | na | na | na | na | na | na |
|
na |
Pt. 10 | 2 | M | CD40LG | c.585dupA; p.L195fs | na | na | na | na | na | 3.25 (4.6–17) | <0.07 (0.17–1.8) | 1.22 (0.6–2.6) |
|
BMT |
IVIG, intravenous immunoglobulin; TMP–SMZ, trimethoprim/sulfamethoxazole; SCIG, subcutaneous immunoglobulin; AZM, azithromycin; BMT, bone marrow transplantation; na, data not available; nv, normal values.
In bold the abnormal values.
aPt.5 was analyzed twice, as a pediatric patient (14 years old) and as an adult patient (19 years old).
bHomozygous mutation.